top of page
Anchor 9
Access all areas: a short guide to formulary visibility
EXPLAINER
May 2024
NICE rejects Enhertu in breast cancer – but a NICE recommendation doesn’t guarantee access
BLOG
March 2024
4 for 24: the trends that could shape access in 2024
BLOG
January 2024
Not NICE: why are women being deprived access to life-changing cancer treatments?
ANALYSIS
March 2023
NICE-recommended lung cancer treatments still absent from formularies
ANALYSIS
August 2023
Access to medicines consistently fails to meet mandatory targets in the UK
ANALYSIS
July 2023
FEATURE
NICE - but not enough. Why evidence is better than assumption when executing your access strategy
"NHS not ready for new Alzheimer's drugs lecanemab and donanemab, warns charity"
OPINION
February 2024
Obesity & diabetes markets are growing – but launch strategies are variable
ANALYSIS
November 2023
Patients are being denied access to EAMS-listed medicines
ANALYSIS
February 2023
Head and neck cancer patients missing out on life-extending treatment
ANALYSIS
July 2023
PwC report exposes glaring disparities in UK healthcare
ANALYSIS
December 2022
FEATURE
Mapping at launch:
Time to update the satnav
VPAG is on the money – data is key to tackling unwarranted variation in adoption of medicines
ANALYSIS
February 2024
CVD: are patients being denied access to life-changing medicines?
ANALYSIS
September 2023
Has Postcode Prescribing got its own category on NHS formularies?
ANALYSIS
April 2023
Endometrial cancer treatment granted EAMS status – but will patients get early access?
ANALYSIS
July 2023
Health inequity?
Let’s get it out of here
ANALYSIS
November 2022
VIDEO
Mastering the maze of UK formularies
FEATURE
Double your sales at launch? Here's how
ANALYSIS
A million patients with stroke, diabetes, asthma or kidney disease are missing out on approved medicines
VIDEO
Tracking formularies:
Five Top Tips
bottom of page